Background: Recent efforts have sought to characterize differences in clinical and pathological characteristics across ethnicities in mRCC (Batai et al CGUC 2018), however, the relationship between ethnicity and treatment outcomes has yet to be explored. We sought to compare survival outcomes across ethnic groups for patients receiving 1L TT for treatment of mRCC. Methods: Patients receiving 1L systemic treatment for mRCC were retrospectively identified from a single institution database from 2009 to present. Patient ethnicity data were collected from electronic health records. Due to the demographics of the patient population, ethnicity was categorized as Non-Hispanic Caucasian American (CA), Hispanic American (HA), or Asian American (AsA). Patients prescribed tyrosine kinase and/or mTOR inhibitors as 1L therapy were included for analysis. PFS and OS were analyzed across ethnic groups and comparisons were performed using the Kaplan Meier Survival Function in SPSS. Results: Of 294 (77:217 F:M) patients with documented survival data, 183 (62%) were CA, 82 (28%) HA, and 29 (10%) AsA. The most frequently used TTs were sunitinib (63%), temsirolimus (10%), pazopanib (7%), sorafenib (5%), and cabozantinib (4%). Median PFS for CA was 5.6 months (95% Confidence Interval [CI]: 4.1-7.1) vs. 4.7 months (95% CI: 3.1-6.2) for HA vs. 4.7 months (95% CI: 2.1-7.3) for AsA. Median OS was 32.0 months (95% CI: 26.2-37.8) for CA vs. 31.7 months (95% CI: 21.1-42.4) for HA vs. 51.7 months (95% CI: 31.6-71.8) for AsA. No significant difference in PFS or OS was calculated across the three ethnic groups (p=0.652 and p=0.435, respectively). Conclusions: The lack of a statistically significant difference in both PFS and OS across ethnic groups is a promising assessment for the current landscape of health disparities in mRCC. As these data are distinct from recent findings identifying disparities in other malignancies (e.g., prostate cancer), multicenter collaborations should be encouraged to validate these findings.